Stockscreener 앱 받기
22.68
3.90%
-0.9443
전일 마감가:
$23.62
열려 있는:
$23.73
하루 거래량:
196.46K
Relative Volume:
0.24
시가총액:
$2.56B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-10.55
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+4.08%
1개월 성능:
+16.65%
6개월 성능:
+12.43%
1년 성능:
+44.95%
1일 변동 폭
$22.49
$23.85
1주일 범위
$21.14
$23.85
52주 변동 폭
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.79 | 2.44B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.78 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.99 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.97 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.10 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.30 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024) - uk.finance.yahoo.com
NewAmsterdam Pharma earnings beat by $0.35, revenue topped estimates - Investing.com UK
NewAmsterdam Pharma Reports Q2 2025 Financial Results - TipRanks
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - The Motley Fool
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises - MarketScreener
NewAmsterdam Pharma Company NV reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $19.1M, vs. FactSet Est of $1.9M - MarketScreener
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire
NewAmsterdam Pharma Co N.V. SEC 10-Q Report - TradingView
Is NewAmsterdam Pharma Company N.V. Equity Warrant the Top Chart Pick This WeekHigh Conviction Intraday Stock Signals Detected - beatles.ru
Published on: 2025-08-04 14:31:37 - metal.it
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockInvest confidently with daily market forecasts - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. stock priceExponentially increasing returns - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Discover stocks with massive upside potential - Jammu Links News
Is NewAmsterdam Pharma Company N.V. Equity Warrant a growth stock or a value stockTurn market volatility into profit opportunities - Jammu Links News
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Build a portfolio with strong long-term growth - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Accelerated wealth building - jammulinksnews.com
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Technical Analysis Support - Jammu Links News
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionExceptional profit margins - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantBoost your returns with professional guidance - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategyExceptional profit potential - Jammu Links News
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversDiscover the fastest growing stocks today - Jammu Links News
Is it the right time to buy NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Stock Market Return Analysis - Jammu Links News
Published on: 2025-08-04 00:09:00 - Jammu Links News
When is NewAmsterdam Pharma Company N.V. stock expected to show significant growthStay ahead with daily market updates - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Game-changing returns - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceTap into rapid wealth building techniques - Jammu Links News
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetCapitalize on market trends with expert guidance - Jammu Links News
Published on: 2025-08-03 11:05:58 - Jammu Links News
Published on: 2025-08-03 06:39:53 - Jammu Links News
What is the risk reward ratio of investing in NewAmsterdam Pharma Company N.V. Equity Warrant stockTurn market volatility into profit opportunities - Jammu Links News
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyInvest smarter with data-backed insights - Jammu Links News
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsPre Market Entry Points To Watch Now - Jammu Links News
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
What institutional investors are buying NewAmsterdam Pharma Company N.V. stockRetirement Planning Guidance To Watch Now - jammulinksnews.com
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Can NewAmsterdam Pharma Company N.V. recover in the next quarterDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
In Broadway trial, a hopeful tune for Alzheimer’s prevention - BioWorld MedTech
NewAmsterdam Pharma Company N.V. Presents Positive Data from Br Broadway Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers At Aaic 2025 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Reverse From Oversold ConditionsReal-Time Trade Insights Spark Market Reactions - metal.it
NewAmsterdam Pharma Presents Positive Data from BROADWAY - GlobeNewswire
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Alzheimers Analysis (1) - MarketScreener
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results - TipRanks
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.28%
2.25%
자본화:
|
볼륨(24시간):